Trial Profile
A clinical study of SAGE-217 in bipolar depression
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2018
Price :
$35
*
At a glance
- Drugs Zuranolone (Primary)
- Indications Bipolar depression
- Focus Therapeutic Use
- 26 Feb 2018 New trial record
- 22 Feb 2018 According to a Sage Therapeutics media release, the company plans to initiate the trial in 2018 and plans to initiate the results in 2018 (2019).